December 1, 2023 | In the News

LIFE SCIENCE LEADER: Ten years ago, Pete DeMuth was wrapping up his Ph.D. in biological engineering at MIT. In parallel, the lab at MIT was watering the sprout of a biotech business rooted in a simple hypothesis—the idea that precisely targeting vaccines to the right location in the body is critical for generating robust immunity against cancer.

November 23, 2023 | In the News

TARGETED ONCOLOGY: Innovative findings in the field of cancer vaccines were presented at the Society for Immunotherapy of Cancer (SITC), focusing on a novel technology directing vaccines into lymph nodes.

November 3, 2023 | Publication

Steinbuck MP, Cabana-Puig X, Palmer E, et al.
Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Nov 1-5, 2023
San Diego, CA

October 10, 2023 | In the News

PHARMA SHOTS: Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies.

September 27, 2023 | Publication

Wainberg ZA, Pant S, Weekes CD, et al.
Presented at the American Association for Cancer Research Special Conference in Cancer Research: Pancreatic Cancer
September 27-30, 2023
Boston, MA

September 15, 2023 | In the News

PHARMA'S ALMANAC: At Elicio Therapeutics, we view real-world data and evidence (RWE) as a critical component for optimizing our drug development process –– particularly the design and execution of our AMPLIFY studies including patient selection and biomarkers of therapeutic response.

August 28, 2023 | In the News

LAW 360: Clinical-stage biotechnology company Elicio Therapeutics Inc. said Monday it has chosen a longtime life sciences attorney to be its general counsel, overseeing the company's legal affairs as it continues its mission...

August 16, 2023 | In the News

VANGUARDS OF HEALTH CARE PODCAST: Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.

August 8, 2023 | In the News

FIERCE Biotech: Interest in developing a vaccine for Epstein-Barr virus, or EBV, has grown as the link between infection and later consequences like multiple sclerosis and cancer has become clear.